For­mer eGe­n­e­sis CEO joins vTv as it tries to make a come­back; Ei­sai nabs Alzheimer’s com­mer­cial ex­ec amid lecanemab push

While Rich Nel­son is out as in­ter­im CEO of vTv Ther­a­peu­tics, he will be con­tin­u­ing as the com­pa­ny’s EVP of cor­po­rate de­vel­op­ment as Paul Sekhri takes the man­tle of pres­i­dent and CEO on Aug. 1.

In Nel­son’s four short months as head of the North Car­oli­na-based biotech, he saw G42 Health­care, a UAE health tech com­pa­ny, in­vest in vTv and agree to col­lab­o­rate on vTv’s Phase III study for a type I di­a­betes treat­ment. Pri­or to Nel­son’s step­ping in as CEO, Deepa Prasad had served as CEO, though she too was on­ly there for a few months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.